Clinical Study Results
How many participants had serious adverse reactions?
The table below shows the serious adverse reactions that happened in at least 1.0% of
participants in any treatment group during the study. There were other serious adverse reactions
that happened during the study, but those happened in fewer participants.
Most common serious adverse reactions during the study
Group 2
Group 1 Durvalumab and Group 3
Durvalumab alone tremelimumab SOC
(out of 369 (out of 371 (out of 352
participants) participants) participants)
Inflammation in the lung 1.4% (5) 2.2% (8) 0.0% (0)
Diarrhea 0.5% (2) 3.0% (11) 0.6% (2)
Scarring of tissue in the lungs 0.3% (1) 1.9% (7) 0.0% (0)
Inflammation of the large
0.3% (1) 1.6% (6) 0.0% (0)
bowel
Liver damage from study
0.0% (0) 1.3% (5) 0.0% (0)
treatment
Feeling tired 0.0% (0) 1.1% (4) 0.0% (0)
Decreased number of red
0.0% (0) 0.0% (0) 3.1% (11)
blood cells
Decreased number of white
blood cells, red blood cells, 0.0% (0) 0.0% (0) 1.7% (6)
and platelets in the blood
There were 0.5% of participants who got durvalumab alone who died from serious adverse
reactions. This was 2 out of 369 participants. These serious adverse reactions were:
• pneumonia caused by a virus
• inflammation in the lung
There were 1.6% of participants who got durvalumab and tremelimumab together who died
from serious adverse reactions. This was 6 out of 371 participants. These serious adverse
reactions were:
• scarring of the tissue in the lung, which happened in 2 participants
• blockage in the small bowel
• inflammation of the pancreas
• liver failure
• sudden death from unknown cause
12